PDCD1 and triple-negative breast carcinoma: In a phase II clinical trial performed by Mediratta et al.'s team, combination therapies of PD-1 and CTAL4 were employed to treat patients with triple-negative breast cancer, and 71% of them achieved excellent clinical outcomes [42].